Quantitation of GD2 synthase mRNA by real-time reverse transcription-polymerase chain reaction: Utility in bone marrow purging of neuroblastoma by anti-GD2 antibody 3F8

Cancer

Volumn 94, Issue 11, 2002, Pages 3042-3048

  Cheung, Irene Y ^a   Lo Piccolo, M Serena ^a   Collins, Nancy ^a   Kushner, Brian H ^a   Cheung, Nai Kong V ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

GD2 synthase; Monoclonal antibody; Neuroblastoma; Purging; Quantitative RT PCR

Indexed keywords

GANGLIOSIDE GD2; IODINE 131; MESSENGER RNA; MONOCLONAL ANTIBODY; SYNTHETASE;

ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; BONE MARROW PURGING; CLINICAL ARTICLE; CLONOGENIC ASSAY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; NEUROBLASTOMA; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL;

ANTIBODIES, MONOCLONAL; BONE MARROW CELLS; BONE MARROW NEOPLASMS; BONE MARROW PURGING; DISEASE PROGRESSION; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; IODINE RADIOISOTOPES; N-ACETYLGALACTOSAMINYLTRANSFERASES; NEUROBLASTOMA; PILOT PROJECTS; RADIOIMMUNOTHERAPY; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SENSITIVITY AND SPECIFICITY;

EID: 0036604377     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.10519     Document Type: Article

References (41)

1. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid
2. Gene marking to trace origin of relapse after autologous transplants of relapse after autologous bone marrow transplantation
3. Direct demonstration that autologous bone marrow transplantation for solid tumors can return a multiplicity of tumorigenic cells
4. Autologous bone marrow transplantation in patients with acute nonlymphocytic leukemia, using ex vivo marrow treatment with 4-hydroperoxycyclophosphamide
5. Hemopoietic reconstitution after repeated autologous transplantation with mafosfamider-purged marrow
6. Magnetic microspheres and monoclonal antibodies for the depletion of neuroblastoma cells from bone marrow: Experiences, improvements and observations
7. Model system for removing neuroblastoma cells from bone marrow using monoclonal antibodies and magnetic immunobeads
8. Immunomagnetic purging of Ewing's sarcoma from blood and bone marrow: Quantitation by real-time polymerase chain reaction
9. Autologous bone-marrow transplantation in CALLA-positive acute lymphoblastic leukemia after in-vitro treatment with J5 monoclonal antibody and complement
10. Eradication of neuroblastoma cells in vitro by monoclonal antibody and human complement: Method for purging autologous bone marrow
11. Photoradiation methods for purging autologous bone marrow grafts
12. Frequent detection of tumor cells in hematopoietic grafts in neuroblastoma and Ewing's sarcoma
13. CD34 selection as a stem cell purging strategy for neuroblastoma: Preclinical and clinical studies
14. A virus-directed enzyme prodrug therapy approach to purging neuroblastoma cells from hematopoietic cells using adenovirus encoding rabbit carboxylesterase and CPT-11
15. Detection of ganglioside GD2 in tumor tissues and sera of neuroblastoma patients
16. Disialoganglioside GD2 loss following monoclonal antibody therapy is rare in neuroblastoma
17. Ganglioside GD2 specific monoclonal antibody 3F8: A phase I study in patients with neuroblastoma and malignant melanoma
18. A phase I study of neuroblastoma with the anti-ganglioside GD2 antibody 14.G2a
19. Decay-accelerating factor protects human tumor cells from complement-mediated cytotoxicity in vitro
20. Surface antigen expression and complement susceptibility of differentiated neuroblastoma clones
21. Lymphokine-activated killer cells targeted by monoclonal antibodies to the disialogangliosides GD2 and GD3 specifically lyse human tumor cells of neuroectodermal origin
22. A mechanism for neutrophil-mediated lysis of human neuroblastoma cells
23. GM-CSF enhances 3F8 monoclonal antibody-dependent cellular cytotoxicity against human melanoma and neuroblastoma
24. Interleukin-2 enhancement of monoclonal antibody-mediated cellular cytotoxicity (ADCC) against human melanoma
25. Phagocytosis of tumor cells by human monocytes cultured in recombinant macrophage colony-stimulating factor
26. Genomic organization and chromosomal assignment of the human B1, 4-N-acetylgalactosaminyltransferase gene
27. Quantitation of marrow disease in neuroblastoma by real-time reverse transcription-PCR
28. GD2 synthase: A new molecular marker for detecting neuroblastoma
29. Ganglioside GM2/GD2 synthetase mRNA is a marker for detection of infrequent neuroblastoma cells in bone marrow
30. N7: A novel multi-modality therapy of high risk neuroblastoma (NB) in children diagnosed over 1 year of age
31. Autologous bone marrow transplantation using unfractionated cells cryopreserved in dimethylsulfoxide and hydroxyethyl starch without controlled-rate freezing
32. Detection of metastatic neuroblastoma in bone marrow: When is routine marrow histology insensitive?
33. Effective purging of neuroblastoma from bone marrow (BM) using IgG3 monoclonal antibody (MoAb) that mediate human complement dependent as well as cell-mediated cytotoxicities
34. Molecular monitoring of tumor cell contamination in leukapheresis products from stage IV neuroblastoma patients before and after positive CD34 selection
35. Myeloablative combination chemotherapy without total body irradiation for neuroblastoma
36. Contamination of peripheral blood stem cell harvests by circulating neuroblastoma cells
37. Sequential detection of tumor cells in the peripheral blood and bone marrow of patients with stage IV neuroblastoma by the reverse transcription polymerase chain reaction for tyrosine hydroxylase mRNA
38. Detection of neuroblastoma cells in CD34+ selected peripheral peripheral stem cells using a combination of tyrosine hydroxylase nested RT-PCR and anti-ganglioside GD2 immunocytochemistry
39. In vivo purging of bone marrow in children with poor-risk neuroblastoma for marrow collection and autologous bone marrow transplantation
40. Quantitative tumor cell content of bone marrow and blood as a predictor of outcome in stage IV neuroblastoma: A Children's Cancer Group study
41. In vivo cytoreduction studies and cell sorting-enhanced tumor-cell detection in high-risk neuroblastoma patients: Implications for leukapheresis strategies